Albany, New York Jan 16, 2019 (Issuewire.com) - Duchenne Muscular Dystrophy (DMD) is a progressive form of muscular dystrophy that occurs primarily in males, though in rare cases may affect females too. DMD causes progressive weakness and loss (atrophy) of skeletal and heart muscles. DMD may also affect learning and memory, as well as communication and certain social-emotional skills. DMD is caused by changes (mutations) in the DMD gene. The DMD gene codes for the protein dystrophin. Dystrophin is mainly made in skeletal and heart muscle cells, but a small amount is also made in nerve cells (neurons) in specific parts of the brain.
DMD is the most common childhood-onset form of muscular dystrophy and affects males almost exclusively. The prevalence is estimated to be 1 in every 3,500 live male births. Age of onset is usually between 3 and 5 years of age. The muscular dystrophies (MD) as a whole are estimated to affect 250,000 individuals in the United States. [2018]. Around 70,000 people have MD or a related condition in the United Kingdom. Duchenne MD is the most common type of MD. In the UK, about 100 boys are born with Duchenne MD each year, and there are about 2,500 people living with the condition in the UK at any one time [2018]. In a study published by Maggie C. Walter et.al. titled, “Recent developments in Duchenne muscular dystrophy: facts and numbers”, researchers estimated the worldwide prevalence of DMD to be 4.78 and according to recent calculations of the German population about 1,900 DMD patients were supposed to live in Germany. [2017]
The goal of Duchenne Muscular Dystrophy (DMD) treatment is to control the symptoms of DMD and related complications caused by severe progressive muscle weakness and loss in order to maximize the quality of life. Various therapies have been developed for treating DMD. Corticosteroids, with all their benefits and side effects, have been the standard treatment. Corticosteroids may improve the strength and function of muscles in people with DMD, including lung function. Steroid options include Deflazacort, Prednisone and Oxandrolone. The medication that have been approved by the Food and Drug Administration (FDA) as orphan products for the treatment of this condition are Deflazacort and Eteplirsen.
The dynamics of Duchenne Muscular Dystrophy market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, raising awareness of the disease, improved bio-markers, incremental healthcare spending across the world and expected launch of emerging therapies during the forecast period of 2018-2027. The Companies like Sarepta Therapeutics (Golodirsen (SRP-4053) and Casimersen (SRP-4045)), NS Pharma (NS-065/NCNP-01), Mallinckrodt (MNK-1411), Hoffmann-La Roche (RG6206), Italfarmaco (Givinostat), PTC Therapeutics (Ataluren) and many others are working towards the development of new treatment therapies for Duchenne Muscular Dystrophy.
The report covers a descriptive overview of the Duchenne muscular dystrophy (DMD), explaining its causes and currently available therapies. Comprehensive insight has been provided into the epidemiology of the Duchenne muscular dystrophy and its treatment in the 7 MM, covering the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom) & Japan. Additionally, an all-inclusive account of both the current and emerging therapies for Duchenne muscular dystrophy are provided, along with the assessment of the impact of new therapies will have on the current treatment landscape. A detailed review of global historical and forecasted Duchenne muscular dystrophy market is included in the report, covering drug outreach in the 7 MM. The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Duchenne muscular dystrophy market
Media Contact
Delveinsight Business Reserarch LLP info@delveinsight.com 09650213330 A-20, Chandra Vihar Sector-7, Dwarka, N Delhi Pin Code-110077, India. https://www.delveinsight.com/
